Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF-mutant advanced melanoma patients: a propensity-matched survival analysis.

Jesper van Breeschoten Michel W J M Wouters Doranne L Hilarius John B Haanen Christian U Blank Maureen J B Aarts Franchette W P J van den Berkmortel Jan-Willem B de Groot Geke A P Hospers Ellen Kapiteijn Djura Piersma Roos S van Rijn Karijn P M Suijkerbuijk Willeke A M Blokx Bert-Jan J Ten Tije Astrid A M van der Veldt Art Vreugdenhil Marye J Boers-Sonderen Alfonsus J M van den Eertwegh

Br J Cancer

Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1118, Amsterdam, 1081HZ, The Netherlands.

Published: May 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9043178	PMC
http://dx.doi.org/10.1038/s41416-022-01772-z	DOI Listing

Publication Analysis

Top Keywords

correction first-line

first-line braf/mek

braf/mek inhibitors

inhibitors versus

versus anti-pd-1

anti-pd-1 monotherapy

monotherapy braf-mutant

braf-mutant advanced

advanced melanoma

melanoma patients

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!

Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF-mutant advanced melanoma patients: a propensity-matched survival analysis.

Download full-text PDF

Publication Analysis

Top Keywords

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?